Sabu Nambi

“Dean, this will be at least the second year in a row where there is a timing dynamic challenge at the top line and seemingly a push out to Q4 or maybe even 2027.”

“Kevin, last quarter you were really helpful in telling us the exome-genome mix, and it would be really helpful if you could tell us what your assumptions are for exome-genome mix in 3Q and then in 4Q. And where do you see yourself exiting this year?”

“As we get closer to 2027 fiscal year, do you have any preliminary thoughts on 27 growth outlook? I know you said you'll give providers full guidance, but then you touched on this a little bit about 20% growth for both NGS and DSPS.”

“How did the CDMO customer orders perform in the quarter, particularly for Cygnus?”

“You mentioned the MRD launch is on track. What is the next tangible catalyst we should look out for? And if it is data, do you know the forum you would share it on either publication or conference?”